NCT05586802View on ClinicalTrials.gov

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Klinefelter Syndrome
Interventions
DRUG

Anastrozole

This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

DRUG

Semaglutide

This will be an experimental treatment for 26 weeks in Group 2 Arm E

DRUG

human chorionic gonadotropin

This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B

DRUG

Testosterone gel

This will be an active comparator for 26 weeks in Group 2 - Arm C

Trial Locations (1)

1011

RECRUITING

Service of Endocrinology, Diabetes & Metabolism, Lausanne

All Listed Sponsors
lead

Georgios Papadakis

OTHER